577 results about "Neurophysins" patented technology

The invention discloses application of Lactobacillus reuteri CCFM1289 with high yield of indoleacetic acid in relieving anxiety and depression, and belongs to the technical field of microorganisms. The Lactobacillus reuteri CCFM1289 can produce heteroauxin at high yield in vivo and in vitro, promote the yield of heteroauxin in fecal flora, relieve anxiety-like and depression-like behaviors of depression mice, relieve HPA hyperfunction, improve the level of brain-derived neurotrophic factor BDNF in hippocampus, promote secretion of 5-HTP and 5-HT in brain, improve the content of heteroauxin in colon, serum and brain, and improve the content of heteroauxin in colon, serum and brain. The compound can be used for improving intestinal flora metabolism imbalance, improving mRNA levels of hippocampal neurogenin-2, synapsin and post-synaptic dense protein 95, maintaining neuronal synaptic function stability, activating AHR signal channels, improving bicortin DCX expression and promoting neurogenesis so as to relieve depression mood, and can be used for drugs, health care products or healthy food for preventing and treating depression.

The invention belongs to the field of drug preparation, and particularly relates to a preparation method and application of a drug delivery system based on hollow mesoporous polydopamine nanoparticles. The drug delivery system comprises hollow mesoporous polydopamine nanoparticles, a drug loaded inside and / or outside the hollow mesoporous polydopamine nanoparticles, and pectin wrapping the hollow mesoporous polydopamine nanoparticles, the medicine is a medicine with a nerve protection effect and an acetylcholin esterase inhibitor. The drug delivery system can reduce proinflammatory cytokines, regulate functions of target immune cells, synergistically reduce necrosis of neurons in intestinal tracts and induce neural crest stem cells in the intestinal tracts to be differentiated into neurons.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an expression inhibitor of an NR4A1 gene in preparation of a medicine for treating wine-dependent withdrawal. It is found that after wine-dependent withdrawal, mice have anxiety behaviors, the NR4A1 level of the prefrontal lobe is increased, and apoptosis-related protein in the prefrontal lobe is increased. Knockout of the forehead NR4A1 gene intervenes the expression level of the NR4A1 gene in the forehead lobe of the mouse, it can be proved that down-regulation of the expression of the forehead lobe NR4A1 gene can rescue apoptosis and damage, caused by alcohol, of cortical neurons of the forehead lobe, relieve anxiety behaviors caused by alcohol withdrawal of the mouse, and have the effect of protecting the brain of the mouse; the inhibitor DIM-C-pPhOH of the NR4A1 protein can reduce the expression of the NR4A1 gene of the prefrontal lobe of an alcohol withdrawal mouse and anxiety-like behaviors caused by alcohol withdrawal, and provides related therapeutic targets and new therapeutic drugs for anxiety dysfunction caused by clinical alcohol dependence and alcohol dependence withdrawal.

The invention discloses novel application of notoginsenoside Rg1, namely application of the notoginsenoside Rg1 in preparation of a cathepsin D (CTSD) inhibitor, the notoginsenoside Rg1 can inhibit CTSD enzyme activity so as to recover lysosome structure and function, relieve endoplasmic reticulum stress reaction and relieve alpha-syn aggregation and dopaminergic neuron apoptosis, has a remarkable protection effect on a Parkinson's disease model, and can be used for preparing a novel anti-inflammatory drug. The invention provides a new thought and a potential drug basis for targeted intervention of Parkinson's disease. The invention discloses a new mechanism that Rg1 plays a role in neuroprotection through a CTSD-lysosome-endoplasmic reticulum stress pathway.

The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg / day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which •modities low-threshold or transient neuronal calcium currents, or •reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

The invention belongs to the field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition with an anti-depression effect, which is prepared from the following medicinal materials by weight: 6g of pericarpium citri reticulatae viride, 6g of pericarpium citri reticulatae, 6g of radix paeoniae alba, 6g of thunberg fritillary bulb, 4.5 g of rhizoma alismatis, 4.5 g of fried gardenia and 4.5 g of moutan bark. The composition regulates functions of hypothalamus-pituitary-adrenal axis (HPA axis) and repairs hippocampal neurons and relieves symptoms such as pleasant sensation loss and behavioral despair of depression patients by relieving qi stagnation, clearing heat, cooling blood, promoting diuresis and reducing phlegm. Experiments prove that the traditional Chinese medicine composition can remarkably improve the sweet water preference rate of depression rats, shorten the forced swimming immobility time, reduce the levels of CRH, ACTH and CORT of plasma and improve pathological injuries of hippocampus tissues. The composition adopts medicinal and edible medicinal materials, is small in side effect and high in safety, and can be prepared into an oral preparation for treating depression.

The invention provides an application of a pentacyclic triterpenoid compound targeting hydroxyl steroid 17-beta dehydrogenase 4. The pentacyclic triterpenoid compound can effectively relieve or treat central nervous system diseases (inflammatory diseases), including central nervous system degenerative diseases or chronic central inflammatory diseases. The pentacyclic triterpenoid compound can maintain the structural stability or activity of hydroxysteroid 17-beta dehydrogenase and maintain the stability or activity of peroxisome, thereby relieving or treating central nervous inflammation. The pentacyclic triterpenoid compound can target hydroxysteroid 17-beta dehydrogenase 4, inhibit neuroglial cell excessive activation related neuroinflammation, relieve neuron damage or death speed and improve a central nervous system cell metabolism microenvironment.

The invention discloses application of PGRN in preparation of products for preventing and treating neuropsychiatric disorder related diseases caused by estrogen deficiency. The invention provides an application of a PGRN protein or a coding gene thereof or a virus expressing the coding gene thereof in preparation of a product with any one of the following functions: 1) preventing or treating or saving neuropsychiatric disorder related diseases caused by estrogen deficiency; 2) preventing or treating perimenopausal anxiety and / or depression symptoms; and 3) relieving anxiety-like behaviors and / or depression-like behaviors caused by estrogen deficiency. The application proves that the PGRN can play a role in protecting neuron damage caused by estrogen deficiency by rescuing CTSD enzyme activity and an autophagy pathway, and prompts that related medicines and measures influencing secretion and content of the PGRN can treat perimenopausal anxiety and depressive symptoms; and a new target and a new idea are provided for clinical treatment and drug development of anxiety and depression symptoms of climacteric women.

The invention relates to the technical field of environmental health risk evaluation, in particular to a method for evaluating the risk of Parkinson's disease induced by environmental pollutants. The method for evaluating the risk of inducing the Parkinson's disease by the environmental pollutants comprises the following steps: carrying out a subacute exposure experiment by taking caenorhabditis elegans as a model organism; observing the transport capacity of the caenorhabditis elegans, observing and counting the abnormal movement ability of the caenorhabditis elegans, and determining the lipofuscin level of the caenorhabditis elegans, the damage degree of dopaminergic neurons, the dopamine level and the expression and aggregation conditions of alpha-synuclein protein, so as to evaluate the risk of the Parkinson's disease induced by environmental pollutants; the environmental pollutant is 6: 2 chlorinated polyfluoroalkyl ether sulfonate. According to the method, the PD toxicity evaluation model is generated by constructing a behavior characteristic and molecular characteristic scheme and combining multi-strain nematode data, and the problem that in the prior art, the risk of inducing PD by environmental pollutants is difficult to comprehensively reveal due to the fact that a single dimension is concerned is solved.

The invention discloses application of Eucommia lignan in preparation of drugs for preventing and treating sepsis in the technical field of medicines. According to the scheme, the effects of the eucommia ulmoides lignan on the aspects of relieving sepsis inflammatory response, regulating cell phenotype and related protein gene expression, relieving neuron damage and the like are fully verified from the cell and animal levels, and the application value of the eucommia ulmoides lignan in preparation of the medicine for preventing and treating sepsis is proved.

The invention provides universally acceptable “off-the-shelf” hypoimmunogenic pluripotent cells and differentiated cardiac, endothelial, neuronal, islet, or retinal pigment cells thereof. Such hypoimmune cells are used to treat patients in need thereof. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis.

The invention belongs to the field of medicines, and discloses application of a stress-induced stem cell extract in treatment of cerebral apoplexy. The inventor finds that stem cells are cultured under proper stress conditions through screening, and the separated stem cell extract (also known as Alritoin) can increase the axon length and dendritic length of normal primary neurons and is beneficial to growth and conduction of nerve fibers; in a pdMCAO model, the volume of cerebral infarction in the acute stage of ischemia of a mouse can be remarkably reduced, the neurological function score can be improved, and a relatively good improvement trend is achieved in the aspect of cognition; in the acute stage of cerebral ischemia reperfusion, the pharmaceutical composition has remarkable effects on reducing the cerebral infarction volume of a mouse, reducing relative edema and improving the neurological function, and is relatively long in medication time window; in a cerebral ischemia reperfusion model, the trend of improving local cerebral blood flow is shown. The allitoin is expected to be developed into a promising drug for cerebral apoplexy, especially a drug for treating ischemic cerebral apoplexy.

The invention discloses a preparation method and application of a novel bird nest alkane diterpenoid compound, and relates to the technical field of medicinal chemistry. The invention aims to solve the problems that chemical synthesis needs harsh conditions and the cost is difficult to control when diterpenoid compounds are obtained in the prior art, and a large amount of resources are wasted and new molecules are difficult to obtain under conventional fermentation conditions. The prepared bird nest alkane type diterpene has dual functions of promoting neurite growth and nourishing neurons, is expected to be developed into a neuroprotective agent, and is used for treating neurodegenerative diseases and peripheral nerve injury diseases; meanwhile, the problems that in the prior art, when the compounds are obtained, conditions needed by chemical synthesis are harsh, the cost is difficult to control, a large number of resources are wasted under conventional fermentation conditions, but new molecules are difficult to obtain, and production and smooth follow-up biological activity research are not facilitated are effectively solved. The invention provides the preparation method and the application of the novel bird nest alkane diterpenoid compound.

The invention provides application of ACT001 in preparation of a medicine for treating spinal cord injury, and relates to the technical field of biomedicine. The parthenolide structure-improved compound ACT001 disclosed by the invention, as a novel neuroprotective drug, has a remarkable effect, and can be used for practically relieving inflammatory response after spinal cord injury, inhibiting formation of glial scars after injury and protecting neurons so as to promote functional recovery. The medicine can improve the lower limb function recovery of the SCI patient, improve the life quality of the patient, and bring a brand new treatment choice for acute and chronic spinal cord injury patients.

The invention provides a cyclic peptide used for treating, improving or preventing nervous system injury of mammals or diseases or pains caused by the injury, neurodegenerative diseases, anxiety or epilepsy or used as a neuronal protective agent, a conjugate containing the cyclic peptide, a pharmaceutical composition containing the cyclic peptide or the conjugate and application of the cyclic peptide and the conjugate.

The invention discloses RVG29 peptide modified tripterine transfersome nasal in-situ gel and a preparation method and application thereof.The in-situ gel is mainly prepared from tripterine, soybean phospholipid, cholesterol, mPEG2000-DSPE, mPEG2000-DSPE-RVG29, sodium deoxycholate and DGG, the RVG29 peptide modified tripterine transfersome nasal in-situ gel can increase the solubility of indissolvable drugs, and the RVG29 peptide modified tripterine transfersome nasal in-situ gel has the advantages that the solubility of the indissolvable drugs is improved; and the RVG29 peptide which can be specifically recognized with a dopaminergic neuron high-expression acetylcholine receptor is modified on the surface of a carrier, so that efficient active targeting endocytosis can be effectively realized, and the RVG29 peptide can be used for treating the Parkinson's disease.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The invention provides application of adiponectin and an adiponectin receptor agonist in treatment of amyotrophic lateral sclerosis. The invention finds that the plasma adiponectin level of an ALS patient is related to the inflammatory factor level, and finds that AdipoR1 and AdipoR2 in the ALS patient are remarkably up-regulated and are related to M1 type macrophage activation. Experiments prove that the adiponectin receptor stimulant can relieve the proinflammatory response of macrophages, regulate the polarization of the macrophages and protect neurons, and the adiponectin receptor stimulant can postpone the occurrence of dyskinesia of ALS patients and prolong the lifetime of the ALS patients. The invention provides a new strategy for diagnosis and treatment of ALS, and has a good clinical application prospect.

The invention relates to the technical field of biological medicine, in particular to application of halofuginone in medicine for treating spinal cord injury. The invention provides application of halofuginone in preparation of a medicine for treating spinal cord injury, application of halofuginone in preparation of a medicine for promoting spinal cord injury repair and application of halofuginone in preparation of a medicine for promoting exercise ability recovery after spinal cord injury. The therapeutic drug can promote functional recovery after spinal cord injury, inhibit activation of microglial cells after spinal cord injury and reduce inflammatory response. In addition, the treatment medicine can prevent neuronal reduction after spinal cord injury.

The invention provides an extraction and detection method of a day lily active matter and application of the day lily active matter in anti-neuritis. Hemerocallis fulva contains various bioactive substances including flavone, polysaccharide and saponin, and the substances have potential application value in the fields of medicines and health care products. The invention provides a method for extracting the active components step by step, and rapid identification and detection are carried out by utilizing technologies such as fluorescence and ultraviolet-visible spectrophotometry. In addition, the invention also develops a detection method for evaluating the anti-neuritis effect of the active substances. Lipopolysaccharide (LPS) is used for stimulation to establish an inflammation model, day lily active substances are added, and the active substances are found to be capable of remarkably inhibiting generation and release of inflammatory factors and promoting growth and differentiation of neurons. Scientific basis is provided for developing new neuritis treatment methods, related drugs and the like.

The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin / activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.

The invention discloses application of ginsenoside Rg5 in preparation of a medicine for treating Alzheimer's disease and an evaluation method, and relates to application of ginsenoside Rg5 in preparation of a medicine for treating Alzheimer's disease. The medicine improves A beta deposition, tau protein phosphorylation and neuron damage by adjusting the intestinal flora structure and metabolite level, and is used for relieving the pathological process of the Alzheimer's disease. The invention has the characteristics of multi-target effect, nerve protection, inflammation resistance and oxidation resistance.

Embodiments of the instant disclosure relate to diagnosis and / or early diagnosis, intervention and / or treatment of Alzheimer's disease (AD). Certain embodiments relate to methods for identifying and isolating / analyzing an enriched population of neuronal, microglial and / or astrocytic exosomes from a sample of a subject and detecting biomarkers of interest on one or more exosomes in the enriched population to diagnose a neurodegenerative condition, Alzheimer's disease (AD), an AD-related dementia / condition, Down Syndrome (DS) or the like at an earlier stage than afforded by current therapies using minimally invasive technologies at reduced costs in time and expenses. Other embodiments relate to assessing interventions and evaluating treatment regimens for neurodegenerative disorders using approaches disclosed herein.

The invention provides multifunctional bionic hydrogel as well as preparation and application thereof in traumatic brain injury treatment, and belongs to the field of biomedical materials. The preparation method comprises the following steps: combining polydopamine modified hemoglobin nanoparticles with curcumin-based carbon quantum dots with anti-inflammatory activity, and embedding into bionic hyaluronic acid-collagen double-network hydrogel, so as to prepare the multifunctional bionic hydrogel. The hydrogel can effectively relieve neuron hypoxia, reduce apoptosis, promote the polarity of microglial cells to be converted into anti-inflammatory phenotype, and significantly down-regulate the expression of S100A8, thereby inhibiting pathological neural immune crosstalk. In a traumatic brain injury model, hydrogel implantation improves the pathological microenvironment, enhances endogenous nerve regeneration, and ultimately results in significant neurological function and cognitive recovery. The multifunctional bionic hydrogel prepared by the invention has a good application prospect in preparation of materials for preventing and / or treating traumatic brain injury.

The invention relates to the technical field of medicines, and discloses six adeno-associated virus (AAV) injections carrying novel artificial chemical genetics receptor gene sequences, and a combinatorial chemical genetics scheme formed by the injections and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The invention relates to the technical field of medicines, and discloses an adeno-associated virus (AAV) injection carrying an artificial chemical genetics receptor gene sequence, and a combinatorial chemical genetics scheme formed by the adeno-associated virus injection and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The invention belongs to the technical field of medicines, and particularly discloses application of CL in medicines for treating and preventing Alzheimer's disease and Parkinson's disease. Researches confirm that CL can significantly improve the athletic ability and chemical tendency ability of Alzheimer's disease caenorhabditis elegans; the service life of the Alzheimer's disease caenorhabditis elegans can be obviously prolonged; the CL can significantly recover damaged neurons of the Parkinson's Caenorhabditis elegans, which prompts that the CL has the potential of preparing drugs for treating neurodegenerative diseases.

The invention discloses a preparation method and application of a sepsis-related encephalopathy model based on HLA II type gene humanized mice. According to the invention, HLA DP401 / DRA-IA beta- / -transgenic humanized mice are utilized, and the HLAII type gene humanized mouse sepsis model is prepared through mouse cecum seroperitoneal infection (CS) and meropenem intervention. The sepsis encephalopathy model can be comprehensively evaluated through indexes such as clinical score MSS, serum and hippocampal tissue inflammatory cytokine detection, hippocampal tissue microglial cell activation, hippocampal neuron spinous process change, transcriptomics, behavioral change and the like, and the sepsis encephalopathy model can be used for screening therapeutic drugs and therapeutic schedules; the HLA II type gene humanized mouse sepsis-related encephalopathy model provided by the invention can be used for infectious encephalopathy pathogenesis research, new drug research and development and safety evaluation.

This invention belongs to the field of pharmaceutical technology, specifically relating to a quinazoline-azaindole compound, its preparation method, and its application in treating Alzheimer's disease. The quinazoline-azaindole compound of this invention regulates NF-κB by inhibiting DYRK1A. k B. A series of signaling pathways, including PI3k-Akt, achieve anti-neuroinflammatory effects; quinazoline-azaindole compounds can reduce the expression of inflammatory factor-related genes in an LPS-induced BV2 microglial inflammation model, thereby reducing the levels of inflammatory factors in the hippocampus and cortex, alleviating neuronal pathological damage caused by neuroinflammation, and improving cognitive impairment caused by neuroinflammation; in summary, quinazoline compounds inhibit DYRK1A and downregulate NF-κB signaling pathways. k It can reduce the expression and release of inflammatory factors, improve brain tissue pathology, and alleviate cognitive impairment through signaling pathways such as B, and has significant clinical application value.